Stocks and Investing
Stocks and Investing
Fri, August 11, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matt O"Brien Maintained (APYX) at Buy with Increased Target to $4.5 on, Aug 11th, 2023
Matt O"Brien of Piper Sandler, Maintained "Apyx Medical Corporation" (APYX) at Buy with Increased Target from $4 to $4.5 on, Aug 11th, 2023.
Matt has made no other calls on APYX in the last 4 months.
There are 3 other peers that have a rating on APYX. Out of the 3 peers that are also analyzing APYX, 1 agrees with Matt"s Rating of Hold. Following is the relevant analyst calls for the last 4 months;
David Turkaly of "JMP Securities" Reiterated at Hold on, Wednesday, May 24th, 2023
These are the ratings of the 2 analyists that currently disagree with Matt;
George Sellers of "Stephens & Co." Initiated at Buy and Held Target at $8 on, Friday, July 14th, 2023 Frank Takkinen of "Lake Street" Maintained at Strong Buy with Increased Target to $9 on, Thursday, June 15th, 2023
Contributing Sources